FMC Biopolymer AS
25Patents
15Active
25Granted
46Portfolio score
Filing activity: Jul 11, 1997 → May 28, 2014 · 13 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7790699B2 | Self-gelling alginate systems and uses thereof | Emerging Cross-Sectional Technologies | 62 | Active |
| US7674837B2 | Gelled biopolymer based foam | Human Necessities | 42 | Expired |
| US6121441A | Procedure for producing uronic acid blocks from alginate | Chemistry; Metallurgy | 33 | Expired |
| US7671100B2 | Gelled biopolymer based foam | Human Necessities | 25 | Active |
| US7671102B2 | Gelled biopolymer based foam | Human Necessities | 21 | Active |
| US6407226B1 | Use of G-block polysaccharides | Chemistry; Metallurgy | 19 | Expired |
| US6165503A | High strength capsules, process of preparing and using the same | Human Necessities | 16 | Expired |
| US7671101B2 | Gelled biopolymer based foam | Human Necessities | 15 | Active |
| US7553656B2 | Mutant strains of Pseudomonas fluorescens and variants thereof, methods for their production, and uses thereof in alginate production | Chemistry; Metallurgy | 7 | Expired |
| US8809521B2 | Delayed self-gelling alginate systems and uses thereof | Chemistry; Metallurgy | 5 | Active |
| US8481695B2 | Self-gelling alginate systems and uses thereof | Emerging Cross-Sectional Technologies | 5 | Active |
| US7972620B2 | Polysaccharide capsules and methods of preparation | Human Necessities | 5 | Active |
| US7790193B2 | Use of alginate matrices to control cell growth | Human Necessities | 3 | Active |
| US6926888B1 | Alginate capsules for use in the treatment of brain tumor | Chemistry; Metallurgy | 2 | Expired |
| US8741872B2 | Self-gelling alginate systems and uses thereof | Emerging Cross-Sectional Technologies | 2 | Active |
| US8168215B2 | Alginate coated, collagen matrix cellular device, preparative methods, and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US7838641B2 | Process for the production of alginate having a high mannuronic acid-content | Human Necessities | 1 | Expired |
| US7893038B2 | Oral immunostimulation of mammals birds and reptiles from (1-4) linked β-D-mannuronic acid | Human Necessities | 1 | Expired |
| US8257727B2 | Medical devices coated with a fast dissolving biocompatible coating | Chemistry; Metallurgy | 0 | Active |
| US9463162B2 | Self-gelling alginate systems and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US7767456B2 | Non-viral gene delivery system | Human Necessities | 0 | Active |
| US7816340B2 | Oral immunostimulation of fish from (1-4) linked β-D-mannuronic acid | Human Necessities | 0 | Expired |
| US8541017B2 | Use of alginate matrices to control cell growth | Human Necessities | 0 | Active |
| US7875449B2 | Oligonucleotide non-viral delivery systems | Human Necessities | 0 | Active |
| US6087342A | Substrates having bound polysaccharides and bacterial nucleic acids | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.